Method for screening peptides for use in immunotherapy

Details Method for screening peptides for use in immunotherapy Method for screening peptides for use in immunotherapy

2011-07-12

2011-07-12

Navarro, Albert (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C530S300000

Reexamination Certificate

active

07976843

ABSTRACT:
Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule, is new. Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule comprising selecting at least one peptide (II) of 8-11 amino acids (aa), potentially representing an epitope for Class I presentation, from a protein against which a cytotoxic T cell (CTL) response is to be raised. (II) corresponds to a non-immunogenic peptide with low affinity for Class I molecules. Variants (IIa) of (II) are prepared in which the N-terminal aa is replaced by Tyr and their immunogenicity detected by identifying those that generate a CTL response against target cells expressing the parent protein. Peptide sequences from which active (IIa) are derived are then identified. Independent claims are also included for the following: (1) immunogenic peptide epitopes (IIa) derived from (I) identified this way; and (2) nucleic acid (III) that encodes chimeric polypeptides (IV) containing one or more, same or different, copies of (IIa).

REFERENCES:
patent: 7425606 (2008-09-01), Kosmatopoulos et al.
patent: 2004/0086518 (2004-05-01), Zanetti
patent: WO 91/04045 (1991-04-01), None
patent: WO 95/27901 (1995-10-01), None
patent: WO 97/35193 (1997-09-01), None
patent: WO 00/02581 (2000-01-01), None
Lee et al (J. of Immunology vol. 163, pp. 6292-6300, 1999).
Gura et al (Science vol. 278, pp. 1041-1042, 1997).
Pogue et al., “Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity”,Proceedings of the National Academy of Science of the United States, vol. 92, No. 18, 1995, pp. 8166-8170.
Hudrisier et al., “Relative implication of peptide residues in binding to major histocompatibility complex class I, H-2D-b: Application to the design of high-affinity, allele-specific peptides”,Molecular Immunology, vol. 32, No. 122, 1995, pp. 895-907.
Oukka et al., “Protection against lethal viral infection by vaccination with nonimmunodominant peptides”,Journal of Medicine, vol. 157, No. 7, Oct. 1, 1996, pp. 3039-3045.
Tourdot et al., “Chimeric peptides: a new approach to enhancing the immunogenicity of peptides with low MHC class I affinity: application in antiviral vaccination”,Journal of Immunology, vol. 159, No. 5, Sep. 1, 1997, pp. 2391-2398.
Plotkin, et al.; (Vaccines W.B. Saunders Company; 1988; p. 571).
Ezzell (J. NIH Res, vol. 7, pp. 46-49, 1995).
Spilter (Cancer Biotherapy, vol. 10, pp. 1-3, 1995).
Boon (Adv. Can. Res., vol. 58, pp. 177-210, 1992).
Gura (Science, vol. 278, pp. 1041-1042, 1997).
Lee et al. (Journal of Immunology, vol. 163, pp. 6292-6300, 1999).
Cornet, Sebastien, et al.: “CpG Oligodeoxynucleotides Activate Dendritic Cells In Vivo and Induce a Funcational and Protective Vaccine Immunity Against a TERT Derived Modified Cryptic MHC Class I-Restricted Epitope”; Available online at www.sciencedirect.com; Vaccine 24 1880-1888, 2006.
Gross, David-Alexandre, et al.: “High Vaccination Efficiency of Low-Affinity Epitopes in Antitumor Immunotherapy”; The Journal of Clinical Investigation, Feb. 2004, vol. 113, No. 3, pp. 425-433.
Bolonaki, Irini, et al.: “Vaccination of Patients with Advanced Non-Small-Cell Lung Cancer with an Optimized Cryptic Human Telomerase Reverse Transcriptase Peptide”; Journal of Clinical Oncology, vol. 25, No. 19, Jul. 1, 2007, pp. 2727-2734.
Mavroudis, D.: “A Phase I Study of the Optimized Cryptic Peptide TERT572Yin Patients with Advanced Malignancies”; Oncology 2006; vol. 70, pp. 306-314.

Affiliated with

Also associated with

Rating

Method for screening peptides for use in immunotherapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for screening peptides for use in immunotherapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for screening peptides for use in immunotherapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2694036